Age-related Normative Values for the Octopus 900 Perimeter

The purpose of this study is to determine normal values of the visual field (VF), corrected for age- and reaction time (RT) using the Octopus 900 perimeter and semi-automated kinetic perimetry (SKP).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

11 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre for Ophthalmology / Institute for Ophthalmic Research, University of Tübingen

Tübingen, Baden-Wurttemberg, 72076, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

maximum spherical ametropia ± 6 Diopters (D)
maximum cylindrical ametropia ± 2 D
distant visual acuity ≥ 1.0 logMAR [20/20] for subjects up to 60 years, ≥ 0.8 logMAR [20/25] for subjects from 61-70 years, ≥ 0.63 logMAR [20/30] for subjects older than 70 years
isocoria, pupil diameter > 3mm
intraocular pressure (air pulse tonometer) ≤ 21mmHg
normal anterior segments
ocular fundus: normal appearance of the cup to disc ratio (CDR) ≤ 0.5, interocular difference of CDR < 0.3
normal macular region, vessels, and peripheral retinal examination (with undilated pupils).

Exclusion criteria

amblyopia
strabismus
ocular motility disorder
diseases of the retina
glaucoma, glaucoma suspect
macular degeneration
IOP > 21 mmHg
abnormal color vision test (ISPP - Ishihara and Standard Pseudoisochromatic Plates = SPP)
history or findings of other neuro-ophthalmological disease
relevant opacities of the central refractive media (cornea, lens, vitreous body)
use of miotic drugs
intraocular surgery (except uncomplicated cataract surgery, more than three months previous to testing)
kerato-refractive surgery (LASIK)
drugs influencing reaction time
drugs indicating severe general diseases (anti-diabetic pharmaceuticals and anti-hypertensive medication were allowed for subjects older than 70 years)
mental diseases (for example psychosis)
pregnancy, nursing
acute infections
heavy smoking (>10 cigarettes /day)
alcohol abuse
diabetic retinopathy
coronary heart disease
stroke
migraine
Raynaud's syndrome
suspected lack of compliance

Treatment and study plan

Octopus 900 perimeter (Haag Streit AG, Koeniz, Switzerland)

Device

We used the following six combinations of Goldmann8,1 stimulus size, stimulus luminance and angular velocity: V4e (64mm², 103', 320cd/m²) at 5°/s, III4e (4mm², 25.7', 320cd/m²) at 5°/s, I4e (0.25mm², 6.45', 320cd/m²) at 2°/s (for the assessment of the blind spot), I3e (0.25mm², 6.45', 100cd/m²) at 5°/s, I2e (0.25mm², 6.45', 32cd/m²) at 3°/s, I1e (0.25mm², 6.45', 10cd/m²) at 3°/s, I1a (0.25mm², 6.45', 4cd/m²) at 2°/s .

The peripheral five isopters, consisting of 24 vectors (every 15° meridian), were presented in random order, while the innermost isopter (I1a) consisted of 12 vectors (every 30° meridian)

Primary outcomes

Measurement of the full Visual Field using semi-automated kinetic perimetry.

Time frame: one day

additional a subgroup of 14 participants were tested at 3 separate sessions within 4 weeks.

Sponsors and collaborators

Lead sponsor

University Hospital Tuebingen

Other

Collaborators

Haag-Streit AG

Registry information

Official study title

Normal Values for the Full Visual Field, Corrected for Age- and Reaction Time, Using Semi-automated Kinetic Testing on the Octopus 900 Perimeter

Acronym: Norm-Oct900

Important dates

Study start: 2006
Primary completion: 2008
Study completion: 2008
First posted: Jan 26, 2012
Registry last updated: Dec 11, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed